Kiniksa Launches Patient Registry (RESONANCE) for Recurrent Pericarditis
02. März 2021 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, March 02, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate...
Kiniksa Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent Pericarditis
23. November 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- PDUFA goal date of March 21, 2021 -- Filing based on positive data from RHAPSODY, which achieved its primary and all major secondary endpoints -- Rilonacept BLA for CAPS transferred to Kiniksa from...
Kiniksa Announces Upcoming Rilonacept Analyst Day
21. September 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of clinical-stage assets designed to...
Kiniksa Presents Data on the Burden of Disease in Patients with Recurrent Pericarditis at the European Society of Cardiology Congress 2020
31. August 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis
16. Juli 2020 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, July 16, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)
29. Juni 2020 07:15 ET
|
Kiniksa Pharmaceuticals, Ltd.
Primary and all major secondary efficacy endpoints were highly statistically significant Rilonacept treatment resulted in a 96% reduction in risk of recurrent pericarditis events (primary efficacy...
Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis
20. November 2019 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019
16. November 2019 12:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Rapid resolution of both reported pain and inflammation as well as improvement in quality of life scores -- Tapering and discontinuation of corticosteroids without pericarditis recurrence - -...
Kiniksa to Present Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019
19. August 2019 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Pharmaceuticals Announces Collaboration with the Myocarditis Foundation for the Pericarditis Community
05. August 2019 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...